Late gadolinium enhancement (LGE) in cardiac magnetic resonance imaging serves as a robust prognostic indicator of adverse outcomes across diverse cardiovascular diseases.
Does myocardial late gadolinium enhancement (LGE) in CMR serve as a reliable risk marker for adverse outcomes in patients with cardiac disease?
LGE in CMR is a robust prognostic indicator for adverse outcomes across various cardiovascular diseases, aiding significantly in risk stratification and the characterization of cardiomyopathies.
Cardiovascular magnetic resonance (CMR) has significantly revolutionized the comprehension and diagnosis of cardiac diseases, particularly through the utilization of late gadolinium enhancement (LGE) imaging for tissue characterization. LGE enables the visualization of expanded extracellular spaces in conditions such as fibrosis, fibrofatty tissue, or edema. The growing recognition of LGE's prognostic capacity underscores its importance, evident in the increasing explicit recommendations within guidelines. Notably, the contemporary characterization of cardiomyopathies relies on LGE-based scar assessment by CMR to a large extent. This review describes the pattern and prognostic value of LGE in detail for various cardiac diseases. Despite its merits, establishing LGE as a reliable risk marker encounters challenges. Limitations arise from the fact that not all diseases show LGE, and it should always be analyzed in the context of all CMR sequences and the patient's medical history. In summary, LGE stands as a robust indicator of adverse outcomes in diverse cardiovascular diseases. Its further integration into routine practice is desirable, necessitating widespread availability and application to accumulate both individual and scientific experience.
Meier et al. (Fri,) conducted a review in Cardiac diseases. Late gadolinium enhancement (LGE) in CMR was evaluated. Late gadolinium enhancement (LGE) in cardiac magnetic resonance imaging serves as a robust prognostic indicator of adverse outcomes across diverse cardiovascular diseases.